Hiroji Iwata
Advanced in Metastatic Brain Tumor

Hiroji Iwata

Nagoya, JP 
Advanced in Metastatic Brain Tumor
Nagoya, JP 
OverviewLocationsClinical Research

Overview

Hiroji Iwata practices in Nagoya, Japan. Iwata is rated as an Advanced expert by MediFind in the treatment of Metastatic Brain Tumor. Their top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Epidermolysis Bullosa Acquisita, Mastectomy, and Hormone Replacement Therapy (HRT).

Their clinical research consists of co-authoring 442 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Metastatic Brain Tumor.

Locations

Nagoya, Japan
Other Locations
Okazaki, Japan
Toon, Japan
Tokyo, Japan
Chikusa, Japan
Sendai, Japan
Atsugi, 2430034, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer
A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Pertuzumab, Docetaxel, Paclitaxel, Nab-paclitaxel, Vinorelbine, Eribulin, Capecitabine, Gemcitabine
Study Phase: Phase 3
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Drug
Study Drugs: Palbociclib, Endocrine Therapy
Study Phase: Phase 3
View 1 Less Clinical Trial

441 Total Publications

Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].
Corrigendum to "Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3": [Ann Oncol 2024; 35: 718-727].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Iwata's expertise for a condition
ConditionClose
View All 18 Advanced Conditions
View All 26 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile